CO2022006066A2 - Agente terapéutico y agente profiláctico para trastornos gastrointestinales funcionales y xerostomía - Google Patents

Agente terapéutico y agente profiláctico para trastornos gastrointestinales funcionales y xerostomía

Info

Publication number
CO2022006066A2
CO2022006066A2 CONC2022/0006066A CO2022006066A CO2022006066A2 CO 2022006066 A2 CO2022006066 A2 CO 2022006066A2 CO 2022006066 A CO2022006066 A CO 2022006066A CO 2022006066 A2 CO2022006066 A2 CO 2022006066A2
Authority
CO
Colombia
Prior art keywords
gastrointestinal disorders
agent
xerostomia
functional gastrointestinal
therapeutic agent
Prior art date
Application number
CONC2022/0006066A
Other languages
English (en)
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of CO2022006066A2 publication Critical patent/CO2022006066A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Se proporciona un agente profiláctico o agente terapéutico novedoso para trastornos gastrointestinales funcionales o xerostomía. La presente invención es un agente terapéutico o agente profiláctico para trastornos gastrointestinales funcionales, que contiene un compuesto de azabencimidazol representado por la siguiente fórmula [1] (cada símbolo en la fórmula es como se describe en la especificación), o una sal farmacéuticamente aceptable del mismo, o un solvato del mismo, como un ingrediente activo.
CONC2022/0006066A 2019-11-13 2022-05-10 Agente terapéutico y agente profiláctico para trastornos gastrointestinales funcionales y xerostomía CO2022006066A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019205436 2019-11-13
PCT/JP2020/042259 WO2021095805A1 (ja) 2019-11-13 2020-11-12 機能性消化管障害及び口腔乾燥症の治療剤及び予防剤

Publications (1)

Publication Number Publication Date
CO2022006066A2 true CO2022006066A2 (es) 2022-08-30

Family

ID=75912669

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0006066A CO2022006066A2 (es) 2019-11-13 2022-05-10 Agente terapéutico y agente profiláctico para trastornos gastrointestinales funcionales y xerostomía

Country Status (13)

Country Link
US (1) US20230000840A1 (es)
EP (1) EP4059503A4 (es)
JP (1) JPWO2021095805A1 (es)
KR (1) KR20220101142A (es)
CN (1) CN114901283A (es)
AU (1) AU2020382209A1 (es)
BR (1) BR112022008457A2 (es)
CA (1) CA3160838A1 (es)
CO (1) CO2022006066A2 (es)
IL (1) IL292813A (es)
MX (1) MX2022005650A (es)
TW (1) TW202124380A (es)
WO (1) WO2021095805A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115399A2 (en) * 2004-04-16 2005-12-08 Neurogen Corporation Imidazopyrazines, imidazopyridines, ans imidazopyrimidines as crf1 receptor ligands
ES2274712B1 (es) * 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
CN101490037B (zh) * 2006-07-11 2013-06-12 大熊制药株式会社 联芳基苯并咪唑衍生物以及包含该衍生物的药物组合物
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
WO2018112840A1 (en) * 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
US20210371412A1 (en) * 2018-05-08 2021-12-02 Nippon Shinyaku Co., Ltd. Azabenzimidazole compounds and pharmaceutical

Also Published As

Publication number Publication date
EP4059503A1 (en) 2022-09-21
CA3160838A1 (en) 2021-05-20
KR20220101142A (ko) 2022-07-19
TW202124380A (zh) 2021-07-01
AU2020382209A1 (en) 2022-06-02
MX2022005650A (es) 2022-06-22
US20230000840A1 (en) 2023-01-05
CN114901283A (zh) 2022-08-12
IL292813A (en) 2022-07-01
WO2021095805A1 (ja) 2021-05-20
BR112022008457A2 (pt) 2022-07-26
EP4059503A4 (en) 2023-11-15
JPWO2021095805A1 (es) 2021-05-20

Similar Documents

Publication Publication Date Title
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
DOP2019000201A (es) Compuestos inhibidores del vih
DOP2019000187A (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
MA39995B1 (fr) Composés destinés à traiter l'amyotrophie spinale
WO2016064082A3 (ko) 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
EP4316591A3 (en) Oxysterols and methods of use thereof
BR112016005270A2 (pt) compostos de aza-piridona, composições farmacêuticas e seus usos
ZA200709251B (en) Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
BR112016009515A8 (pt) derivado de sulfonamida, composição farmacêutica, agente terapêutico ou um agente preventivo para doença inflamatória, e, inibidor de integrina a4ß7.
CO2017003321A2 (es) Inhibidores de gingipaina de lisina
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
AR117655A1 (es) Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
WO2015002755A3 (en) Compounds for the treatment of malaria
CO2022006066A2 (es) Agente terapéutico y agente profiláctico para trastornos gastrointestinales funcionales y xerostomía
BR112019007591A2 (pt) inibidores de bromodomínios
WO2016163818A3 (ko) 2-메톡시-4-(3-(4-메톡시페닐)프로필-1-엔-1-일)페놀을 유효성분으로 함유하는 염증성 질환 또는 관절염 치료 또는 예방용 약학적 조성물
BR112012024346A2 (pt) agente terapêutico ou agente profilático para a doença de alzheimer
CL2020000251A1 (es) Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico.
AR078167A1 (es) Dispersion solida que comprende un agente anti-vih